MACK Key Stats
- Merrimack's CEO Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 15
- Nasdaq stocks posting largest percentage decreases May 13
- Merrimack Reports First Quarter 2013 Financial Results GlobeNewswire May 13
- Q1 2013 Merrimack Pharmaceuticals Inc Earnings Release - Time Not Supplied May 13
- Dimon Talks of Quitting, Post Cereal Jumps Ahead of Earnings Hot Stock Minute May 13
- Earnings Scheduled For May 13, 2013 Benzinga May 13
- MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Fina... May 13
- Stocks Hitting 52-Week Lows Benzinga May 6
- Predicting Biotech Stock Moves Using Top Consensus Picks By Legendary Fund Manag... May 5
- Merrimack to Present at Multiple Investor Conferences This Spring noodls May 2
MACK Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Merrimack Pharmaceuticals is down 29.59% over the last year vs S&P 500 Total Return up 31.40%, Threshold Pharmaceuticals down 9.98%, and Immunogen up 25.24%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for MACK
Pro Report PDF for MACK
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download MACK Pro Report PDF
Pro Strategies Featuring MACK
Did Merrimack Pharmaceuticals make it into our Pro Portfolio Strategies?